Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "antisense transcript to FGA" is a long non-coding RNA transcribed from the opposite strand of the FGA (Fibrinogen alpha chain) genomic locus. Antisense RNAs are frequently implicated in regulation of their sense counterpart's transcription, often through modulation of chromatin architecture, transcription initiation rates, transcript processing, and RNA stability. While antisense transcription can affect the abundance and dynamics of protein-coding transcripts such as FGA, these RNAs are generally not directly targeted by small molecules or biologics and are not considered conventional therapeutic targets[1][3][5]. The designation "ENSG00000306549" is an Ensembl identifier, and there are no common aliases or target-family assignments for this locus. Currently, there are no drugs or clinical therapeutics designed to specifically modulate this antisense transcript, and its biological or pathological importance in humans beyond regulatory RNA function remains undetermined.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antisense transcript to fibrinogen alpha chain.